Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC40A1 | Q9NP59 | 10/20 | 1.00 |
| ▸ | MEN1 | O00255 | 5/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.48 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.46 |
| ▸ | KLF5 | Q13887 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALOX15B | O15296 | 1/20 | 0.44 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | HTR1A | P08908 | 1/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11997175 | 0.94 | SLC40A1 (0.88) | SLC40A1MEN1KMT2ATDP1ALDH1A1 | |
| SCHEMBL11973810 | 0.85 | SLC40A1 (1.00) | SLC40A1MEN1KMT2ATDP1ALDH1A1 | |
| SCHEMBL11997125 | 0.79 | SLC40A1 (0.84) | SLC40A1MEN1KMT2ATDP1ALDH1A1 | |
| SCHEMBL7196771 | 0.74 | TDP1 (1.00) | SLC40A1MEN1KMT2ATDP1ALDH1A1 | |
| SCHEMBL11469089 | 0.72 | SLC40A1 (0.56) | SLC40A1MEN1KMT2ATDP1MAPT | |
| SCHEMBL11469088 | 0.72 | SLC40A1 (0.56) | SLC40A1MEN1KMT2ATDP1ALDH1A1 | |
| SCHEMBL28667552 | 0.70 | MEN1 (0.56) | SLC40A1MEN1KMT2ATDP1ALDH1A1 | |
| SCHEMBL4296647 | 0.70 | SMN1; SMN2 (0.54) | SLC40A1MEN1KMT2ATDP1ALDH1A1 | |
| SCHEMBL11997124 | 0.69 | SLC40A1 (0.81) | SLC40A1MEN1KMT2ATDP1ALDH1A1 | |
| SCHEMBL14212958 | 0.69 | KDM4E (0.62) | SLC40A1MEN1KMT2ATDP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3180328-A1 | QUINOLINE DERIVATIVES USEFUL AS UBIQUITINATION INHIBITORS | Rigel Pharmaceuticals, Inc. (US) | 2017-06-21 | — | — | EP | claimed |
| US-20160068490-A1 | UBIQUITINATION INHIBITORS | MIDCAP FINANCIAL TRUST | 2016-03-10 | — | — | US | claimed |
| WO-2016025779-A1 | QUINOLINE DERIVATIVES USEFUL AS UBIQUITINATION INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2016-02-18 | — | — | WO | claimed |
| US-10040766-B2 | Ubiquitination inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2018-08-07 | — | — | US | disclosed |
| EP-3180328-A1 | QUINOLINE DERIVATIVES USEFUL AS UBIQUITINATION INHIBITORS | Rigel Pharmaceuticals, Inc. (US) | 2017-06-21 | — | — | EP | disclosed |
| EP-2675526-B1 | NOVEL SULFONAMINOQUINOLINE HEPCIDIN ANTAGONISTS | VIFOR (INTERNATIONAL) AG (CH) | 2017-02-01 | — | — | EP | disclosed |
| US-20160068490-A1 | UBIQUITINATION INHIBITORS | MIDCAP FINANCIAL TRUST | 2016-03-10 | — | — | US | disclosed |
| WO-2016025779-A1 | QUINOLINE DERIVATIVES USEFUL AS UBIQUITINATION INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2016-02-18 | — | — | WO | disclosed |
| US-9102688-B2 | Sulfonaminoquinoline hepcidin antagonists | VIFOR (INTERNATIONAL) AG (CH) | 2015-08-11 | — | — | US | disclosed |
| US-9102688-B2 | Sulfonaminoquinoline hepcidin antagonists | VIFOR (INTERNATIONAL) AG (CH) | 2015-08-11 | — | — | US | disclosed |
| US-9102688-B2 | Sulfonaminoquinoline hepcidin antagonists | VIFOR (INTERNATIONAL) AG (CH) | 2015-08-11 | — | — | US | disclosed |
| US-20140364424-A1 | Novel Sulfonaminoquinoline Hepcidin Antagonists | VIFOR (INTERNATIONAL) AG (CH) | 2014-12-11 | — | — | US | disclosed |
| US-20140364424-A1 | Novel Sulfonaminoquinoline Hepcidin Antagonists | VIFOR (INTERNATIONAL) AG (CH) | 2014-12-11 | — | — | US | disclosed |
| US-20140364424-A1 | Novel Sulfonaminoquinoline Hepcidin Antagonists | VIFOR (INTERNATIONAL) AG (CH) | 2014-12-11 | — | — | US | disclosed |
| US-20120214803-A1 | Novel Sulfonaminoquinoline Hepcidin Antagonists | VIFOR (INTERNATIONAL) AG (CH) | 2012-08-23 | — | — | US | disclosed |
| US-20120214803-A1 | Novel Sulfonaminoquinoline Hepcidin Antagonists | VIFOR (INTERNATIONAL) AG (CH) | 2012-08-23 | — | — | US | disclosed |
| US-20120214803-A1 | Novel Sulfonaminoquinoline Hepcidin Antagonists | VIFOR (INTERNATIONAL) AG (CH) | 2012-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214803-A1 | Novel Sulfonaminoquinoline Hepcidin Antagonists | HAMP, SLC40A1, FTH1 | SLC40A1 2/4885MEN1 2680/4885KMT2A 3298/4885 |
| US-20160068490-A1 | UBIQUITINATION INHIBITORS | MDM2, RBX1, NEDD4 | SLC40A1 4627/4885MEN1 2624/4885KMT2A 501/4885 |
| US-20140364424-A1 | Novel Sulfonaminoquinoline Hepcidin Antagonists | HAMP, SLC40A1, FTH1 | SLC40A1 2/4885MEN1 2680/4885KMT2A 3298/4885 |
| US-10040766-B2 | Ubiquitination inhibitors | MDM2, RBX1, NEDD4 | SLC40A1 4627/4885MEN1 2624/4885KMT2A 501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.